Comparing Amneal Pharmaceuticals (NASDAQ:AMRX) and Contineum Therapeutics (NASDAQ:CTNM)

Amneal Pharmaceuticals (NASDAQ:AMRX) and Contineum Therapeutics (NASDAQ:CTNM) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Amneal Pharmaceuticals and Contineum Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.17%	283.50%	7.79%
Contineum Therapeutics	N/A	-25.48%	-24.28%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Amneal Pharmaceuticals and Contineum Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0	2	8	0	2.80
Contineum Therapeutics	1	2	2	0	2.20

Amneal Pharmaceuticals currently has a consensus price target of $23.00, indicating a potential upside of 7.50%. Contineum Therapeutics has a consensus price target of $21.40, indicating a potential upside of 127.56%. Given Contineum Therapeutics’ higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than Amneal Pharmaceuticals.

Risk and Volatility

Amneal Pharmaceuticals has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.

Earnings and Valuation

This table compares Amneal Pharmaceuticals and Contineum Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02 billion	2.26	$72.06 million	$0.42	50.94
Contineum Therapeutics	$50.00 million	7.08	-$59.98 million	($1.77)	-5.31

Amneal Pharmaceuticals has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Amneal Pharmaceuticals beats Contineum Therapeutics on 12 of the 14 factors compared between the two stocks.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology. The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets.

About Contineum Therapeutics

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological, inflammatory and fibrotic diseases. The company is based in San Diego, California, and was previously known as Pipeline Therapeutics. Its development programs include PIPE-307, an investigational M1 receptor antagonist being studied for neurological conditions, including relapsing-remitting multiple sclerosis. Contineum is also developing PIPE-791, an investigational LPA1 receptor antagonist for fibrotic lung diseases and related conditions.